We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Invitrogen PD-Direct™ Pre-Conference Workshop at Bioprocess International

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Invitrogen, has announced PD-Direct™, its fully integrated service for customized bioprocess development, is holding a pre-conference workshop, ‘The Science of Bioproduction’, on Monday 23 April 2007 at Bioprocess International, Le Palais Des Congrès, Paris, France.

According to Invitrogen, this PD-Direct™ run workshop will provide advice on everything required to take a biotherapeutic from bench to production and will be ideal for scientists in biotech companies that are looking to take antibodies, recombinant proteins, viruses or cell therapies into clinical development.

The workshop, which is run by PD-Direct™’s Bryan Monroe, a bioprocess expert with many years’ experience in major pharma companies, will include insights from PD Direct™’s specialists, Dr Laurie Donahue-Hjelle and Peggy Lio, on vector construction, cell line development and media optimization, as well as product characterization and scale-up information.

Laurie Donahue-Hjelle, Director, Cell Line Development for Invitrogen PD-Directä stated: "Well thought out bioprocess development will lead to efficient timelines, quality product and low cost of goods and it is never too early in clinical development to implement this level of planning.”

Donahue-Hjelle added: “By attending ‘The Science of Bioproduction’ workshop, scientists can tap into the many decades of expertise in process development and cell culture manufacturing the PD-Directä team has. They will learn about the bioprocess activities that are critical for reducing risk and saving time, which could help them avoid costly mistakes and result in producing highly profitable biotherapeutics.”